Association for Molecular Pathology (AMP) Online Educational Resources

This site houses an ever-expanding selection of AMP-developed educational online content which includes 60-minute webinars given by leaders in the field of molecular pathology and diagnostics addressing their cutting-edge research; introductory courses to help pathologists, residents, laboratory directors, and technologists learn the basics of molecular pathology; and meeting highlights that feature the best talks given during the AMP Annual Meeting and Global Congress. Established courses and practice guidelines are also available.

Type Website
CME Available Yes
Cost Free and discounted prices for AMP members; limited free resources and at cost for non AMP members

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.


  • Genomic Testing
    • P-GT2A:   Patient Care
      • 2A1:   Discuss the indications for genomic testing - specifically the benefits, risks, and alternatives
      • 2A2:   Explain the implications of placing genomic test results in the patient’s medical record
      • 2A3:   Discuss the possibility of incidental findings and how they will be handled
      • 2A4:   Discuss risks of having genomic testing done: e.g., psychological implications for the individual as well as the family; the potential for discrimination; and the potential effect on insurance coverage.
      • 2A5:   Explain to the patient issues of costs and financial coverage of genomic testing
      • 2A6:   Order, interpret, and communicate the results of appropriate genomic tests, within the physician’s scope of practice
      • 2A7:   Provide referral to an appropriate specialist for genomic testing of a condition outside the physician’s scope of practice
      • 2A8:   Respond to the results of an abnormal genetic screening test, such as newborn screening, including immediate management and appropriate referral
    • P-GT2B:   Knowledge for Practice
      • 2B1:   Describe the major forms of genomic variability
      • 2B2:   Explain how different genomic changes may result in different phenotypes
      • 2B3:   Recognize that genomic tests require interpretation with respect to the patient’s clinical status (e.g., pathogenic, likely pathogenic, benign)
      • 2B4:   Explain the concepts of analytic validity, clinical validity, clinical utility as they relate to genomic testing
      • 2B5:   Recognize that medically ’non-actionable’ genomic results can be useful to the patient and family (i.e., personal utility)
    • P-GT2H:   Personal and Professional Development
      • 2H1:   Engage in continuing education regarding advances in genomic medicine and changing indications for and interpretation of genomic testing
  • Patient Treatment Based on Genomic Results
    • P-PM3A:   Patient Care
      • 3A1:   Identify medical conditions and drug responses that have a strong genetic component
      • 3A2:   Recognize that variants affecting drug responses found in a patient may also have implications for other family members
      • 3A3:   Discern the potential clinical impact of genetic variation on risk stratification and individualized treatment
    • P-PM3B:   Knowledge for Practice
      • 3B1:   Appreciate the importance of genetic diversity of humans and the abundance of genetic variants in each individual genome
      • 3B2:   Identify single-gene disorders that may be amenable to targeted pharmacological therapy
      • 3B3:   Recognize that genomic test results may guide choice of therapy for multifactorial disorders
      • 3B4:   Recognize that there is variability in the phenotypic expression of genetic variants and in response to therapy
      • 3B5:   Recognize that the effects of some medications are strongly influenced by inherited or somatically acquired genetic variation
    • P-PM3D:   Interpersonal and Communication Skills
      • 3D1:   Discuss benefits, risks, and alternatives of various preventive and therapeutic approaches driven by genomic findings
      • 3D2:   Communicate clearly with other medical professionals involved in the care of the patient about the therapeutic implications of the genetic information garnered about the patient 3D3. Discuss pharmacogenomics implications for future health
      • 3D3:   Discuss pharmacogenomics implications for future health
    • P-PM3H:   Personal and Professional Development
      • 3H1:   Maintain the medical knowledge and clinical competence in genomics required for the provision of therapy
      • 3H2:   Be familiar with the available databases and resources relevant to genetic variation, including ongoing clinical trials involving patients with genetic disorders, pharmacogenomics, and patient-oriented Internet resources from reliable organizations
  • Somatic Genomics
    • P-SG4A:   Patient Care
      • 4A1:   Identify or facilitate identification of patients who may benefit from genomic testing of tissue
      • 4A2:   Explain the benefits and limitations of somatic genomic testing to the patient, including implications regarding treatment of their condition and clarification of his/her prognosis
      • 4A3:   Ensure that tissue biopsy procedures are coordinated to make certain that appropriate and sufficient material is obtained for testing
      • 4A4:   Integrate genomic testing results into the patient-care plan
    • P-SG4B:   Knowledge for Practice
      • 4B1:   Explain the concept of somatic genetic change
      • 4B2:   Describe the role of genomic changes in the pathophysiology and treatment of cancer
      • 4B3:   Explain how genomic testing can be used to guide choice of therapy and adjust drug dosage in patients with cancer
    • P-SG4C:   Practice-Based Learning and Improvement
      • 4C1:   Maintain an awareness of and follow evidence-based guidelines and other professional resources regarding somatic genetic disorders appropriate to the physician’s scope of practice
    • P-SG4F:   Systems-Based Practice
      • 4F1:   Maintain a dialog with the clinical laboratory to ensure that the appropriate test(s) are ordered and interpreted in the context of the patient’s clinical status
      • 4F2:   Be prepared to refer patients to clinical trials designed to evaluate new approaches to cancer therapy
    • P-SG4H:   Personal and Professional Development
      • 4H1:   Keep up-to-date with progress in the diagnosis and treatment of cancer and other tissue-based disorders